Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Sickle Cell Disease: early-phase trial registry
95 of 214 indexed Sickle Cell Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #43 of 28,707 conditions by registered trial count.
214 US clinical trials · 95 currently recruiting · #43 of 28,707 conditions by registered trial count
Sickle Cell Disease: 214 US clinical trials tracked, 95 recruiting.
Sickle Cell Disease is the subject of 214 registered US clinical trials on ClinicalTrials.gov, 95 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 17 of these trials.
Enrollment posture brief
Registry condition sickle-cell-disease
OPEN 95 | RECR 44% | LATE 14 | EARLY 87 | RANK #43 | SPON 17
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Sickle Cell Disease lists 95 open slots (44% of 214 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Sickle Cell Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Sickle Cell Disease is recruiting above its size-band peers.
95 of 214 indexed trials (44.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Sickle Cell Disease trials is spread across many organizations.
St. Jude Children's Research Hospital accounts for 17 of 214 trials (7.9%). 101 distinct sponsors appear on at least one study for this condition label.
-
Most Sickle Cell Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 214 trials that report a genuine target (sentinel values excluded). 150 of those (70.1%) plan for fewer than 100 participants.
-
Sickle Cell Disease research is mostly interventional.
160 interventional and 54 observational studies make up this index (74.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
214 total, page 2 of 5
Cannabidiol in Sickle Cell Disease
Icahn School of Medicine at Mount Sinai
NCT06930703
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
Emory University
NCT06979492
Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease
National Human Genome Research Institute (NHGRI)
NCT06944067
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
University of Illinois at Chicago
NCT03121001
Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease
University of Pennsylvania
NCT07316478
Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease
Children's National Research Institute
NCT06770010
A Long-term Follow-up Study in Patients Who Received BEAM-101
Beam Therapeutics
NCT07373639
Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait
UConn Health
NCT07083531
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
St. Jude Children's Research Hospital
NCT05583721
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
New York Medical College
NCT02675959
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
Ann & Robert H Lurie Children's Hospital of Chicago
NCT04688411
School Readiness Intervention for Preschool Children With Sickle Cell Disease
St. Jude Children's Research Hospital
NCT06367192
Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain
Louisiana State University Health Sciences Center in New Orleans
NCT06773715
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
University of California, San Francisco
NCT06260891
Cutaneous Hydration Assessment in SCD
Enrico Novelli
NCT05210114
Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease
Mayo Clinic
NCT07222475
Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises
University of Maryland, Baltimore
NCT06184126
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
University of California, Davis
NCT06016634
Ultrasound Acute Chest Syndrome Sickle Cell Disease
Indiana University
NCT06880679
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Vertex Pharmaceuticals Incorporated
NCT05477563
Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease
Boston Children's Hospital
NCT06555939
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
National Heart, Lung, and Blood Institute (NHLBI)
NCT05904093
Gene Editing For Sickle Cell Disease
St. Jude Children's Research Hospital
NCT06506461
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Memorial Sloan Kettering Cancer Center
NCT05736419
Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
Fulcrum Therapeutics
NCT07431398
Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease
Children's Hospital Medical Center, Cincinnati
NCT05012631
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Disc Medicine
NCT07187973
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
University of Pennsylvania
NCT05730205
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
Emory University
NCT02447874
Early Life Exposures Among Children With Sickle Cell Disease
University of Alabama at Birmingham
NCT05377372
Sickle Cell Children's Exercise Study (SuCCESs)
University of Maryland, Baltimore
NCT06074198
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
Enrico Novelli
NCT04925492
Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease
Emory University
NCT07090668
Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease
University of Illinois at Chicago
NCT07402811
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
EpiDestiny
NCT04055818
Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
Children's National Research Institute
NCT05099874
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Mitchell Cairo
NCT04099966
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Abdullah Kutlar
NCT01245179
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
Kamau Therapeutics
NCT04819841
Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
University of Pittsburgh
NCT04109820
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
St. Jude Children's Research Hospital
NCT06442761
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
Children's National Research Institute
NCT06358638
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
Daniel Bauer
NCT06647979
Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease
Mark Walters, MD
NCT04774536
A Pilot Study on Neuroimaging in SCD: Part of The Boston Consortium to Cure Sickle Cell Disease
Boston Children's Hospital
NCT04166526
CHOICES3: Sickle Cell Disease Parenting CHOICES
University of Florida
NCT05292781
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
Forma Therapeutics
NCT04624659
Kidney Function in Sickle Cell Anemia
Kenneth Ataga MD
NCT03277547
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
Agios Pharmaceuticals
NCT05031780
Stroke Prevention in Young Adults With Sickle Cell Anemia
Vanderbilt University Medical Center
NCT04808778
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 48 |
| Phase 3 | 11 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Sickle Cell Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Sickle Cell Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Sickle Cell Disease page
214 registered trials, 95 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 95 Sickle Cell Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Jude Children's Research Hospital sponsors the most Sickle Cell Disease trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sickle Cell Disease condition card totals 214 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.